Cargando…

Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]

BACKGROUND: Adjuvant therapy to ORT with probiotic bacteria for infants with acute watery diarrhea has been under active investigation. Most studies have been done in the developed world showing benefit only for viral mild gastroenteritis. We evaluated the effect of a milk formula containing one bil...

Descripción completa

Detalles Bibliográficos
Autores principales: Salazar-Lindo, Eduardo, Miranda-Langschwager, Percy, Campos-Sanchez, Miguel, Chea-Woo, Elsa, Sack, R Bradley
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517719/
https://www.ncbi.nlm.nih.gov/pubmed/15345099
http://dx.doi.org/10.1186/1471-2431-4-18
_version_ 1782121787391213568
author Salazar-Lindo, Eduardo
Miranda-Langschwager, Percy
Campos-Sanchez, Miguel
Chea-Woo, Elsa
Sack, R Bradley
author_facet Salazar-Lindo, Eduardo
Miranda-Langschwager, Percy
Campos-Sanchez, Miguel
Chea-Woo, Elsa
Sack, R Bradley
author_sort Salazar-Lindo, Eduardo
collection PubMed
description BACKGROUND: Adjuvant therapy to ORT with probiotic bacteria for infants with acute watery diarrhea has been under active investigation. Most studies have been done in the developed world showing benefit only for viral mild gastroenteritis. We evaluated the effect of a milk formula containing one billion (10(9)) cfu/ml of Lactobacillus casei strain GG (LGG) upon duration and severity of diarrhea in infants in an environment with more severe acute diarrhea, where etiologic agents other than rotavirus are involved more frequently, and where mixed infections are more prevalent. METHODS: Male infants aged 3–36 months brought for treatment of acute watery diarrhea of less than 48 hours were eligible. After rehydration was completed with the WHO's oral rehydration solution, patients were randomly assigned to receive a milk formula either containing LGG or not. Stool volume was periodically measured using a devise suited to collect stools separate from urine. Duration of diarrhea was estimated based on stools physical characteristics. RESULTS: Eighty nine patients received the placebo milk formula and ninety received the LGG containing formula. Both groups were comparable in their baseline characteristics. Total stool output was significantly larger (p = 0.047) in the LGG group (247.8 ml/kg) than in the placebo group (195.0 ml/kg). No significant differences were found in duration of diarrhea (58.5 hours with LGG vs. 50.4 hours with placebo), rate of treatment failure (21.1% with LGG vs. 18.0% with placebo), and proportion of patients with unresolved diarrhea after 120 hours (12.2% with LGG vs. 12.5% with placebo). The rate of stools with reducing substances after 24 hours of treatment increased significantly in both groups (from 41.4% to 72.2% with LGG and from 45.9% to 68.0% with placebo). CONCLUSION: This study did not show a positive effect of LGG on the clinical course of acute watery diarrhea. Positive beneficial effects of LGG, as had been reported elsewhere, could have been masked in our study by worsening diarrhea due to transient lactose malabsorption. Further studies with low-lactose or non-lactose conveyors of LGG are desirable.
format Text
id pubmed-517719
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5177192004-09-19 Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048] Salazar-Lindo, Eduardo Miranda-Langschwager, Percy Campos-Sanchez, Miguel Chea-Woo, Elsa Sack, R Bradley BMC Pediatr Research Article BACKGROUND: Adjuvant therapy to ORT with probiotic bacteria for infants with acute watery diarrhea has been under active investigation. Most studies have been done in the developed world showing benefit only for viral mild gastroenteritis. We evaluated the effect of a milk formula containing one billion (10(9)) cfu/ml of Lactobacillus casei strain GG (LGG) upon duration and severity of diarrhea in infants in an environment with more severe acute diarrhea, where etiologic agents other than rotavirus are involved more frequently, and where mixed infections are more prevalent. METHODS: Male infants aged 3–36 months brought for treatment of acute watery diarrhea of less than 48 hours were eligible. After rehydration was completed with the WHO's oral rehydration solution, patients were randomly assigned to receive a milk formula either containing LGG or not. Stool volume was periodically measured using a devise suited to collect stools separate from urine. Duration of diarrhea was estimated based on stools physical characteristics. RESULTS: Eighty nine patients received the placebo milk formula and ninety received the LGG containing formula. Both groups were comparable in their baseline characteristics. Total stool output was significantly larger (p = 0.047) in the LGG group (247.8 ml/kg) than in the placebo group (195.0 ml/kg). No significant differences were found in duration of diarrhea (58.5 hours with LGG vs. 50.4 hours with placebo), rate of treatment failure (21.1% with LGG vs. 18.0% with placebo), and proportion of patients with unresolved diarrhea after 120 hours (12.2% with LGG vs. 12.5% with placebo). The rate of stools with reducing substances after 24 hours of treatment increased significantly in both groups (from 41.4% to 72.2% with LGG and from 45.9% to 68.0% with placebo). CONCLUSION: This study did not show a positive effect of LGG on the clinical course of acute watery diarrhea. Positive beneficial effects of LGG, as had been reported elsewhere, could have been masked in our study by worsening diarrhea due to transient lactose malabsorption. Further studies with low-lactose or non-lactose conveyors of LGG are desirable. BioMed Central 2004-09-02 /pmc/articles/PMC517719/ /pubmed/15345099 http://dx.doi.org/10.1186/1471-2431-4-18 Text en Copyright © 2004 Salazar-Lindo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Salazar-Lindo, Eduardo
Miranda-Langschwager, Percy
Campos-Sanchez, Miguel
Chea-Woo, Elsa
Sack, R Bradley
Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title_full Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title_fullStr Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title_full_unstemmed Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title_short Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: A randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]
title_sort lactobacillus casei strain gg in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [isrctn67363048]
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517719/
https://www.ncbi.nlm.nih.gov/pubmed/15345099
http://dx.doi.org/10.1186/1471-2431-4-18
work_keys_str_mv AT salazarlindoeduardo lactobacilluscaseistraingginthetreatmentofinfantswithacutewaterydiarrheaarandomizeddoubleblindplacebocontrolledclinicaltrialisrctn67363048
AT mirandalangschwagerpercy lactobacilluscaseistraingginthetreatmentofinfantswithacutewaterydiarrheaarandomizeddoubleblindplacebocontrolledclinicaltrialisrctn67363048
AT campossanchezmiguel lactobacilluscaseistraingginthetreatmentofinfantswithacutewaterydiarrheaarandomizeddoubleblindplacebocontrolledclinicaltrialisrctn67363048
AT cheawooelsa lactobacilluscaseistraingginthetreatmentofinfantswithacutewaterydiarrheaarandomizeddoubleblindplacebocontrolledclinicaltrialisrctn67363048
AT sackrbradley lactobacilluscaseistraingginthetreatmentofinfantswithacutewaterydiarrheaarandomizeddoubleblindplacebocontrolledclinicaltrialisrctn67363048